

Word Count (Total): 4552  
Word Count (Abstract): 249  
Tables: 2  
Figures: 4

## **A Preliminary Investigation Of Repetitive Transcranial Magnetic Stimulation Applied To The Left Dorsolateral Prefrontal Cortex In Treatment Seeking Participants With Cannabis Use Disorder**

Gregory L. Sahlem<sup>a</sup>, Bohye Kim<sup>a</sup>, Nathaniel L. Baker<sup>b</sup>, Brendan L. Wong<sup>a</sup>, Margaret A. Caruso<sup>c</sup>, Lauren A. Campbell<sup>c</sup>, Irakli Kaloani<sup>a</sup>, Brian J. Sherman<sup>c</sup>, Tiffany J. Ford<sup>a</sup>, Ahmad H. Musleh<sup>a</sup>, Jane P. Kim<sup>a</sup>, Nolan R. Williams<sup>a</sup>, Andrew J. Manett<sup>c</sup>, Ian H. Kratter<sup>a</sup>, Edward B. Short<sup>c</sup>, Terese K. Killeen<sup>c</sup>, Mark S. George<sup>b,d</sup> and, Aimee L. McRae-Clark<sup>b,d</sup>

<sup>a</sup>Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA  
Departments of <sup>b</sup>Public Health Sciences and <sup>c</sup>Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA  
<sup>d</sup>Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina, USA

### **Corresponding author:**

Gregory L. Sahlem, MD.  
Assistant Professor  
Stanford University Department of Psychiatry and Behavioral Sciences  
401 Quarry Road  
Palo Alto, CA, 94304  
650-497-0902  
[gsahlem@stanford.edu](mailto:gsahlem@stanford.edu)

**Declaration of Interests:** GLS has collaborated with MagVenture and MECTA as part of investigator-initiated trials. He additionally consults for and has equity in the company Trial Catalyst. TJF is employed by Magnus Medical and holds stock/equity options. NRW is a named inventor on Stanford-owned intellectual property relating to accelerated TMS pulse pattern sequences and neuroimaging-based TMS targeting; he has served on scientific advisory boards for Otsuka, NeuraWell, Magnus Medical, and Nooma as a paid advisor; and he has equity/stock options in Magnus Medical, NeuraWell, and Nooma. EBS is a paid consultant for Neuronetics and is an equity holder of Bodhi Neurotech. MSG has the following disclosures; Babystrong (patent co-holder), Brainsway (unpaid consultant, research grant, donated equipment for research trials), Magnus Medical (unpaid scientific Advisor), Magstim (unpaid consultant, donated equipment for research trials), MECTA (unpaid consultant, research grant, donated equipment for research grant), Microtransponder (DSMB member), Neuronetics (unpaid consultant, research grant, donated equipment for research), NeoSync (unpaid consultant, DSMB member), Neuralief (scientific advisory board, research grant, and Sooma (scientific advisory board), and he is an editor of the Elsevier journal Brain Stimulation. ALM has received research support from PleoPharma. None of the other authors have any relevant conflicts to disclose.

**Funding Sources:** The National Institutes of Health supported this work via grant numbers K23DA043628 (PI: Sahlem, NIH/NIDA), K12DA031794 (Co-PI's McRae-Clark and Gray, NIH/NIDA), and K24DA038240 (PI: McRae-Clark, NIH/NIDA).

**Author Contributions:** GLS, NLB, EBS, TTK, MSG, and ALM designed the experiment. GLS, BLW, MAC, LAC, IK, BJS, TJF, AHM, NRW, AJM, IHK, EBS, and TTK performed the study. GLS, BK, NLB, and JPK analyzed the study's findings. GLS, BK, NLB, JPK, and ALM wrote the first draft of the manuscript. All authors critically reviewed and edited the manuscript.

**Clinicaltrials.gov identifiers:** NCT03144232.

## Highlights:

This phase-2 RCT tested the efficacy of prefrontal rTMS for cannabis use disorder

The study paradigm was safe and feasible, and participants tolerated rTMS well

The active-group had numerically more weeks of abstinence during follow-up

The active-group had fewer days-per-week of cannabis use during follow-up

More rTMS and a longer follow-up may result in a larger effect in future studies

## **Abstract:**

**Background:** Cannabis use disorder (CUD) is a common and consequential disorder. When applied to the dorsolateral prefrontal cortex (DLPFC), repetitive transcranial magnetic stimulation (rTMS) reduces craving across substance use disorders and may have a therapeutic clinical effect when applied in serial sessions. The present study sought to preliminarily determine whether serial sessions of rTMS applied to the DLPFC had a therapeutic effect in CUD.

**Methods:** This study was a two-site, phase-2, double-blind, randomized-controlled-trial. Seventy-two treatment-seeking participants (37.5% Women, mean age  $30.2 \pm 9.9$ SD) with  $\geq$ moderate-CUD were randomized to active or sham rTMS (Beam-F3, 10Hz, 20-total-sessions, with cannabis cues) while undergoing a three-session motivational enhancement therapy intervention. The primary outcome was the change in craving between pre- and post- treatment (Marijuana Craving Questionnaire Short-Form—MCQ-SF). Secondary outcomes included the number of weeks of abstinence and the number of days-per-week of cannabis use during 4-weeks of follow-up.

**Results:** There were no significant differences in craving between conditions. Participants who received active rTMS reported numerically, but not significantly, more weeks of abstinence in the follow-up period than those who received sham rTMS (15.5%-Active; 9.3%-Sham; rate ratio = 1.66 [95% CI: 0.84, 3.28];  $p=0.14$ ). Participants who received active rTMS reported fewer days-per-week of cannabis use over the final two-weeks of the follow-up period (Active vs. Sham:  $-0.72$ ;  $Z=-2.33$ ,  $p=0.02$ ).

**Conclusions:** This trial suggests rTMS is safe and feasible in individuals with CUD and may have a therapeutic effect on frequency of cannabis use, though further study is needed with additional rTMS-sessions and a longer follow-up period.

**Key Words:** Cannabis use disorder, marijuana, cannabis, addiction, TMS, transcranial magnetic stimulation.

## 1.0 Introduction:

Cannabis Use Disorder (CUD) is a common condition with well-documented adverse effects<sup>1–3</sup> and concordantly high demands for treatment<sup>4,5</sup>. The incidence of frequent cannabis use and CUD may be increasing in the United States and worldwide<sup>6,7</sup> with increasing legalization and decreased perceived risk<sup>8</sup>. The frequency of daily cannabis use has also risen in recent years in the United States—potentially further increasing the risk of an increased incidence of CUD in the future<sup>9</sup>. Though there are promising pharmacologic treatments in the pipeline<sup>10–13</sup>, no medication has distinguished itself as clearly effective in the treatment of CUD. Further, although consistently demonstrating a beneficial effect, studies testing behavioral therapies for CUD have resulted in moderate effects<sup>14</sup>. As such, there remains a need to develop new therapeutics for CUD.

Repetitive transcranial magnetic stimulation (rTMS) works via the principles of magnetic induction and long-term potentiation<sup>15–17</sup> and can focally alter circuit function in the brain<sup>18–20</sup>. Trials applying serial applications of rTMS in a variety of neuropsychiatric conditions have demonstrated that by varying the location of stimulation and the treatment paradigm, it is possible to derive a therapeutic benefit in different illnesses, and rTMS is now cleared by the US Food and Drug Administration for the treatment of Major Depressive Disorder<sup>21–23</sup>, Obsessive Compulsive Disorder<sup>24</sup>, and Tobacco Use Disorder<sup>25</sup>. In line with the several indications for treatment, there has been increasing promise that rTMS may become a therapeutic option across addictions, including CUD<sup>26</sup>. Studies have suggested rTMS has the potential to effect behavioral aspects of addiction<sup>27–30</sup>, engage its neurocircuitry<sup>20,31,32</sup>, and, when serial sessions of rTMS are applied, have therapeutic effects. Several neurocircuit targets have emerged for study in therapeutic trials, with early promising results for the left dorsolateral prefrontal cortex (DLPFC)<sup>33</sup>, the frontal pole<sup>34</sup>, the dorsomedial prefrontal cortex<sup>35</sup>, and the anterior-insula / inferior frontal gyrus<sup>25</sup>, although not all trials have resulted in a beneficial effect<sup>36</sup>.

Our group and others<sup>37</sup> have explored the potential effect of applying rTMS to the left DLPFC, first in non-treatment-seeking participants with CUD<sup>38</sup> and then participants with CUD who were interested in reducing their use of cannabis<sup>39</sup>. Our early findings suggested that a single-session of rTMS could be feasibly applied to participants with CUD, was generally well tolerated, and may reduce the purposefulness aspect of craving<sup>38</sup>. In a subsequent study, we found that it was infeasible to deliver daily sessions of rTMS for two-weeks in treatment-seeking participants with CUD. However, those participants who did attend daily sessions reported less craving and reduced cannabis use that persisted 4-weeks after receiving rTMS<sup>39</sup>. The findings from our preliminary work and other therapeutic studies in other addictive disorders applying rTMS to the DLPFC, suggested therapeutic promise for CUD, albeit with a treatment paradigm that differed from daily applications. Both data<sup>40–42</sup> and clinical experience suggest it is possible to get a therapeutic effect using rTMS even if treatments are delivered less frequently than daily. Based on both trial experience and qualitative discussions with participants from our pilot treatment trial, we hypothesized that delivering study-treatments twice each week would be feasible and have a clinical effect. We subsequently designed the present phase-2 study to preliminarily determine if rTMS applied to the DLPFC twice-weekly had the potential to help treatment-seeking participants with CUD reduce their cannabis use. Specifically, we hypothesized that participants receiving active-rTMS would have reduced craving and more weeks of abstinence than participants receiving sham-rTMS.

## 2.0 Materials and Methods:

### 2.1 Study Design:

This study was an outpatient, two-site, double-blind, randomized, parallel-designed, sham-controlled trial. Two sites conducted the trial (initially at the Medical University of South Carolina between August 2017 and March 2020, and, subsequently, at Stanford University between April 2021 and June 2022). There was a 1:1 allocation to active or sham rTMS without stratifying variables. Participants were evaluated at a screening visit and underwent study-treatment over five-weeks, where they attended two study-treatment-visits per week (and received two study-rTMS-treatments per visit) for twenty total study-treatments delivered over ten study-treatment-visits. Participants met with a study therapist during three of the study visits and received Motivational Enhancement Therapy (MET)<sup>13,43</sup>. Participants returned two- and four-weeks after the final study-treatment-visit to complete follow-up assessments. We compensated participants for their time and travel and used prize-based contingency management to reinforce visit attendance. This trial was conducted in accordance with the Declaration of Helsinki, was approved by the Institutional Review Boards of each study site, and was pre-registered on [clinicaltrials.gov](https://clinicaltrials.gov) ([NCT03144232](https://doi.org/10.1111/NCT03144232)). Participants provided written informed consent before engaging in study-procedures.

## 2.2 Participant Selection:

We recruited participants from addiction medicine clinics and from the community via media advertisements. Participants were included if: a) they were between the ages of 18 and 60 years; b) they met the Diagnostic and Statistical Manual for Mental Disorders—DSM-5—criteria for  $\geq$ moderate cannabis use disorder; c) they had a desire to quit or reduce cannabis use; and d) they had a positive urine drug test for cannabis. Participants were excluded if: a) they were pregnant or breast-feeding; b) they met DSM-5-criteria for another  $\geq$ moderate substance use disorder (other than nicotine use disorder); c) they were regularly taking medications with central nervous system effects; d) they had a history of psychotic disorder, bipolar disorder, or any other psychiatric condition requiring acute treatment; e) they had a Hamilton Rating Scale for Depression—HRSD<sub>24</sub> score greater than 10 indicating clinically relevant depressive symptoms; f) they had a history of dementia or other cognitive impairment; g) they had active suicidal ideation or a suicide attempt within the past 90-days; h) they had any contraindications to receiving rTMS<sup>44,45</sup> or MRI<sup>46</sup>, or; i) they had any unstable general medical condition.

## 2.3 Assessments:

Participants were allowed to use cannabis ad libitum prior to the screening visit, though they were instructed not to arrive intoxicated (verified via clinical assessment). During the screening visit, participants underwent a medical and psychiatric evaluation which included the Mini-International Neuropsychiatric Interview (MINI)<sup>47</sup>, the Hamilton Rating Scale for Depression (HRSD<sub>24</sub>)<sup>48</sup>, and the structured criteria for CUD as found in the Structured Clinical Interview for the DSM-5<sup>49</sup>. We quantified CUD severity using the Cannabis Use Disorder Identification Test (CUDIT)<sup>50</sup> and assessed motivation to change using the Marijuana Contemplation Ladder<sup>51</sup>. We collected the Marijuana Problem Scale as part of the Brief Marijuana Dependence Counseling Personal Feedback Report<sup>43</sup>. We assessed current symptoms of cannabis withdrawal using the Cannabis Withdrawal Scale (CWS)<sup>52</sup>. We recorded twenty-eight days of previous cannabis use using the Time-Line Follow-Back (TLFB)<sup>53</sup>. We defined a cannabis use session as any cannabis use separated by an hour or more since the last cannabis use session and approximated the number of grams used at each session. We also assessed alcohol and other substance use using qualitative urine drug testing including testing for ethyl-glucuronide (T-Cup®, Guangzhou Wondfo Biotech Co., LTD).

Eligible participants received rTMS during ten study-visits. Participants were instructed to abstain from cannabis and other substances for at least 24-hours prior to rTMS visits #1 and #10 (verified by saliva drug testing; SalivaConfirm® testing, Confirm Biosciences, Inc.) and we collected immediate pre- and post- data on those visits. Participants completed a visual cue-reactivity task<sup>54</sup> during functional magnetic resonance imaging (fMRI) at the beginning of the pre- and post- visits (results will be reported elsewhere) and then we measured craving using the Short-Form of the Marijuana Craving Questionnaire (MCQ-SF)<sup>55</sup> approximately 20-minutes later. Additionally, data was collected for cannabis use via the TLFB (preceding week) and symptoms of withdrawal via the CWS (after 24-hours of abstinence). We used the Architect C4000 system from Abbott Laboratories to measure urine cannabinoids and creatinine, and the creatinine-corrected urine cannabinoid level (ng/mg) was derived by dividing the cannabinoid level (ng/ml) by the creatinine level (mg/ml).

The remainder of the study-visits were conducted while participants were allowed to use cannabis ad libitum (though were not intoxicated during visits). We collected TLFB data continuously and assessed symptoms of withdrawal using the CWS at each visit. Participants met with the study team two- and four-weeks following their last rTMS-visit, during which cannabis use was assessed for the 4-weeks of follow-up using the TLFB and urine cannabinoids.

We defined weeks of abstinence from cannabis as those weeks where participants did not report any cannabis use. On the visits where urine cannabinoids were collected, self-reported weeks of abstinence were verified as abstinent, defined in<sup>56</sup> as a 25% drop in creatinine-corrected cannabinoid level from the prior level and an absolute level of <200ng/ml.

We identified adverse events at each visit using open-ended questions and considered them in the context of their severity, seriousness, and possible relation to the study-intervention.

## 2.4 Repetitive Transcranial Magnetic Stimulation (rTMS) Paradigm:

Participants received active or sham rTMS via a MagVenture MagPro X100 double-blinded device using a B65 coil. During each session, participants received 4000 pulses of stimulation at 10Hz (5-seconds on, 10-seconds off) while interacting with cannabis cues<sup>57</sup>. We delivered stimuli at 120% of the participants resting motor threshold<sup>58</sup>. We targeted the left dorsolateral prefrontal cortex using the Beam-F3 method<sup>59</sup>. We delivered two-sessions of rTMS at each of the ten study-treatment-visits with a 30-minute inter-session-



interval. Sham stimulation consisted of low current electrical stimuli coinciding with each click of the TMS coil. We assessed blinding following the first and last study-session by asking participants to guess their treatment allocation and to rate their confidence on a Likert scale.

## 2.5 Study Hypotheses (Supplemental Figure-1):

The primary hypothesis (Aim-1) of the experiment, as pre-specified on [clinicaltrials.gov](#), was that the active-rTMS-group would have a reduction in behavioral craving (via the MCQ-SF) between the immediate pre- and post- visits relative to the sham-rTMS-group. We chose immediate pre- and post- time-points (rather than longitudinal craving) because those assessments were completed with at least 24-hours of abstinence from cannabis.

The primary clinical exploratory analysis (Aim-2a), as pre-specified on [clinicaltrials.gov](#), was that the active rTMS group would have more weeks of urine cannabinoid-verified abstinence in the follow-up period than the sham rTMS group. We selected the four-weeks of follow-up as the time frame given it followed the delivery of the entire course of rTMS and would be less subject to any supportive clinician effect that twice-weekly meetings might have. We were able to confirm abstinence using creatinine-corrected urine cannabinoids at the two- and four- week follow-up visits. We additionally tested the hypothesis that the active-rTMS-group would have fewer days-per-week of cannabis use in the follow-up period than the sham rTMS-group (Aim-2b), though this was an exploratory hypothesis that was not pre-specified. We chose abstinence and days-per-week of cannabis use as the clinical outcomes because they are not influenced by the methodologic problems inherent in assessing cannabis use (variable THC concentrations, amount used per cannabis-use-session, varying routes of administration, etc.). Further, weeks of abstinence and days-per-week of cannabis use have been associated with improved quality of life, reduced marijuana-related problems, and decreased symptoms of depression and anxiety<sup>60-62</sup>.

## 2.6 Analysis Plan:

We calculated descriptive statistics such as means and standard deviations (SD) for all continuous variables and proportions for categorical variables. We compared demographic, screening, blinding, and adverse event variables (compiled using MEDra criteria) across condition and site using t-tests or the Wilcoxon Rank Sum test for continuous variables and the Chi-Square or Fisher's Exact test for categorical variables.

For Aim-1, we utilized a generalized linear mixed-effects model (GLMM) to perform the analyses, with the full ITT sample (N=72) and the total MCQ-SF score as the dependent measure. We used two types of a priori models for each analysis: 1) a three-way interaction model which included an interaction between treatment, site, and time, as well as the main effects of treatment, site, time, and all pairwise interactions between the main terms, and 2) a two-way interaction model which included treatment, time, an interaction between treatment and time, and site. We considered pre- and post- variables with a strong clinical rationale for inclusion in covariate adjustment including the amount of time since the last cannabis use, CWS score, the days-per-week of cannabis use, the grams of cannabis used per day, and the number of cannabis use sessions per day.

To assess group differences in the number of weeks of abstinence in the follow-up period (Aim-2a), a Poisson regression model was fit with the total number of weeks of self-reported abstinence in the four-week follow-up period as the dependent variable and treatment, site, and treatment by site interaction as independent variables. We conservatively imputed missing values as non-abstinent, thereby including the total ITT sample. We additionally performed a sensitivity analysis for weeks of abstinence by including the weeks preceding the 9th rTMS-treatment visit and immediate post-visit since these two weeks represent the time following the delivery of a total of 16-sessions of rTMS (a similar dose to early rTMS for depression studies). We calculated the relative risk of having a week of abstinence as a measure of the effect size, along with 95% confidence intervals. We used creatinine-corrected urine cannabinoids to verify self-reported abstinence at follow-up weeks 2 and 4, and calculated the proportion that these two methods were concordant.

To evaluate group differences in the number of days of cannabis use (Aim-2b), we utilized a GLMM with the number of days-per-week of cannabis use as the dependent measure. We included participants in the model who had follow-up data (the completer sample; N=51) and given the apparent divergence in days-per-week of cannabis use in the final two-weeks of the follow-up period, we chose to focus our analysis on that period.

Residual normality was assessed for each of the above models using QQ-plots. We included sex in all models to detect a potential effect, but when no significant effects were found, we excluded sex from the subsequent final models. Apart from craving, this was a pilot trial and not powered a priori to detect statistically significant differences; however, statistically significant *p*-values are noted when observed. When reported, a

level of  $\alpha = 0.05$  was used (two-tailed), and no adjustments for multiple comparisons were made for this preliminary investigation. Effect sizes at each time point were estimated as Cohen's  $d$  using means and pooled standard deviations. Statistical analyses were conducted using R software (version 4.2.1, GNU project) and SAS version 9.4 (Cary, NC).

### 3.0 Results:

#### 3.1 Participants and Trial Feasibility (Figure-1 and Table-1):

We assessed a total of 128 participants for eligibility between the two sites, enrolled 91 during the screening visit, and randomized 72 during an initial study treatment visit (comprising the Intent-To-Treat—ITT—sample). Fifty-one participants completed all study visits (comprising the completer sample). Participants tolerated study-treatment well (mean final treatment dose  $114.7\% \pm 9.4\%$  rMT-active;  $118.9\% \pm 3.7\%$  rMT-sham). There were no statistically significant differences between conditions on any baseline variable. There were, however, several site differences that reached statistical significance (Supplemental Table-1), including race and ethnicity, number of daily tobacco users, total HRSD<sub>24</sub> score, number of DSM-5 criteria for CUD, MPS total score, number of grams of cannabis smoked per day, and number of days using cannabis in the baseline 28-days.

#### 3.2 Cannabis Craving (Figure-2):

Craving as measured by the MCQ-SF total score decreased in both active and sham conditions between pre- and post-treatment course assessments ( $45.8 \pm 18.5$ SD to  $27.7 \pm 15.1$ SD in the active-group;  $45.2 \pm 16.3$ SD to  $22.6 \pm 11.1$ SD in the sham-group; active vs. sham: 4.05;  $Z=0.98$ ,  $p=0.33$  when adjusting for site). None of the exploratory covariates were significantly related to the change in the MCQ-SF score and minimally changed the treatment effects.

#### 3.3 Abstinence from Cannabis (Figure-3 and Supplemental Table-2):

Participants who received active stimulation reported a numerically higher percent of weeks of abstinence in the four-week follow-up period (15.5%) than those who received sham stimulation (9.3%) with a relative risk of having a week of abstinence of 1.67 [95%CI: 1.03, 2.31]. However, the average number of weeks of abstinence in the 4-week follow-up period did not significantly differ between the two-conditions when adjusting for the site (rate ratio = 1.66 [95% CI: 0.84, 3.28];  $p=0.14$ ). Of note, much of the abstinence effect was driven by the Stanford sample (31.3%-active; 15.0%-sham; rate ratio=2.08 [95% CI: 0.95, 4.58];  $p=0.07$ ), with minimum abstinence in either the active or sham group in the MUSC sample (3.6%-active; 5.0%-sham; rate ratio=0.71 [95% CI: 0.16, 3.19];  $p=0.66$ ). Creatinine-corrected urine cannabinoids were concordant with self-reported abstinence in 84.6% of observations. The number of weeks of self-reported abstinence was similar in the final 6-weeks of the study (14.9%-active, 9.0%-sham; rate ratio for active vs. sham = 1.63 [95% CI: 0.93, 2.87];  $p=0.09$ ).

#### 3.4 Days-Per-Week of Cannabis Use (Figure-4):

The mean number of days-per-week of cannabis use decreased in both conditions between the pre-intervention week and the four weeks of follow-up but diverged between the active and sham groups in the final two-weeks of follow-up. The active group appeared to have a more durable decrease in days-per-week of cannabis use ( $6.0 \pm 1.2$ SD-pre,  $4.0 \pm 2.7$ SD-post,  $3.4 \pm 2.9$ SD-1-week-FU,  $3.7 \pm 2.8$ SD-2-week-FU,  $3.7 \pm 3.1$ SD-3-week-FU, and  $3.6 \pm 2.8$ SD-4-week-FU) than did the sham group ( $6.0 \pm 1.4$ SD-pre,  $4.0 \pm 2.8$ SD-post,  $2.8 \pm 3.0$ SD-1-week-FU,  $3.8 \pm 2.5$ SD-2-week-FU,  $4.8 \pm 2.5$ SD-3-week-FU, and  $5.1 \pm 2.4$ SD-4-week-FU). The reduction in days-per-week of cannabis use from follow-up week two to follow-up week four differed significantly by treatment condition (active vs. sham: -0.72;  $Z=-2.33$ ,  $p=0.02$ ). The effect sizes, as measured by Cohen's  $d$  during the post-treatment divergence, were 0.39 in week 3, 0.57 in week 4 and 0.47 when combining the final two weeks. The Stanford sample again had a larger effect on days-per-week of use in the final week of the follow-up period (Cohen's  $d=0.72$ ), though a small effect was also present in the MUSC sample (Cohen's  $d=0.34$ ).

#### 3.5 Adverse Events (AEs—Table-2):

We included all adverse events (AEs) that were rated as definitely, probably, possibly, and probably not related to the study intervention in the analysis. A total of 30 AEs occurred in 23 participants. There were no severe or serious AEs. Headache was the most common AE, followed by fatigue, and a series of AEs that occurred only once. Twenty-nine of the 30 AEs were categorized as mild and one as moderate (a participant in the sham group experienced a more substantial headache). Two participants (both in the active condition)

described a clear onset of symptoms consistent with the cannabis abstinence syndrome<sup>63</sup> coinciding temporally with when they stopped using cannabis. We coded these clusters of AEs as definitely not related to study-treatment and did not include them in the AE analysis. Other AEs that were more likely to have been withdrawal related than rTMS related (including insomnia, irritability/mood swings, and increased anxiety) were included in the AE analysis, given they were singular symptoms (as opposed to clearly clustered symptoms).

### 3.6 Blinding (Supplemental Table-3):

Following the first rTMS study visit, 91.2% of the active and 73.5% of the sham groups believed they received active rTMS ( $p=0.11$ ). Following the full course of rTMS, 61.5% of the active and 60.9% of the sham groups believed they received active rTMS ( $p=0.96$ ).

## **4.0 Discussion:**

In this two-site, phase-2, randomized, sham-controlled clinical trial, we demonstrated the feasibility of delivering an rTMS intervention along with three-sessions of motivational enhancement therapy to treatment-seeking participants with moderate or severe CUD. Participants tolerated rTMS well with few adverse events, and the retention rate in this study compares well to other CUD studies. Contrary to our hypothesis, we did not find between group differences in craving reduction. However, both groups experienced a reduction in craving scores. We observed numerically (but not statistically significantly) more weeks of abstinence in the active rTMS group than the sham rTMS group in the follow-up period, driven mainly by a large effect in the Stanford sample. The number of days-per-week of cannabis use decreased during active treatment in both groups, though remained reduced in the follow-up period in the active group but not in the sham group, an effect that differed significantly in the final two-weeks of follow-up.

As expected, rTMS was well tolerated with only mild AEs observed in the active condition. The AE profile of rTMS compares favorably to those described in studies using medications reporting a positive effect, including quetiapine, varenicline, and, nabiximols<sup>11-13</sup>. Similarly, the overall retention rate in this trial compared favorably to other clinical trials, with 70.8% of the sample retained (retention rates for pharmacotherapy trials have ranged from 36% to 65%<sup>11-13,64-70</sup>). Notably, the active group had a higher retention rate than the sham group suggesting that study treatment was well tolerated. Blinding was intact for this study and we believe the sham procedures can be relied upon for future investigations.

Most but not all studies across substance use disorders have suggested that rTMS applied to the left-DLPFC reduces craving<sup>71</sup>. As such, it is surprising that the participants within the sham group of our trial reported numerically decreased craving relative to the active group. Our initial explanation for this unexpected finding was that a covariate must have driven the post-treatment craving score. However, in exploratory modeling, none of the final models significantly predicted the final MCQ-SF score, and the inclusion of candidate covariates minimally changed the models. The limited power available in our medium-sized sample, however, may have reduced the ability of the explored covariates from becoming significant predictors during modelling. Another possibility is that the focus and timeframe (the immediate time of its administration) of the MCQ-SF limited its ability to detect between-group differences in the context of this clinical trial. Notably, no pharmacotherapy trial (including full agonist therapy<sup>11,65</sup>) has observed a between-group change in craving over the course of treatment using the MCQ-SF, even when finding a clinical effect. The MCQ-SF subsequently may be better at detecting acute differences<sup>38,57</sup> than longitudinal ones. Future clinical trials might consider including a measure that captures a longer time period and has shown sensitivity to treatment effects in other substance use disorders.

The moderate between-group clinical effect-sizes we observed in the follow-up period of our trial were in the range of, or larger, than other treatment trials observing suggestions of efficacy in CUD. The between-group relative risk of having a week of abstinence in the present trial approached but did not meet the observed effect in our recent phase-2 varenicline trial<sup>13</sup>. Self-reported weeks-of-abstinence were verified using cannabinoid testing in nearly 85% of cases, supporting the validity of participants reporting abstinence. The between-group effect size of days-per-week of cannabis use of Cohen's  $d=0.47$  was comparable to the two pharmacotherapy trials that observed a difference in days-per-week of use (Cohen's  $d$  of 0.39-0.55)<sup>11,13</sup>, and to behavioral trials using a wait-list group as a comparator (Hedges'  $g$  of 0.44 in meta-analysis)<sup>14</sup>. Of note, though we did hypothesize that participants receiving active rTMS would have fewer days of cannabis use in the follow-up period, our observed effect did not emerge until the final two-weeks of follow-up, which was not pre-hypothesized. All participants received an evidence-based three-session course of MET and had a high rate of clinical contact with supportive clinical staff, which in addition to placebo effects may explain the similar clinical improvement in both groups during the acute treatment period. The divergence in days-per-week of cannabis



use subsequently occurred when the intensity of clinical visits was reduced and could represent an increased durability in the effect following treatment. Two other recent sham-controlled rTMS for alcohol use disorder trials observed a similar phenomenon where the main treatment-effects were reflected in increased durability in the follow-up period<sup>34,35</sup>. Future rTMS for addiction trials might focus further on durability in an extended follow-up period.

Our study sample differed by site in several baseline variables and the preliminary effect size of the therapeutic effects of rTMS also differed by site, most notably in the number of weeks-of-abstinence. Both samples heavily used cannabis at baseline; however, the sample in California reported more days-per-week of use and numerically more use sessions per day at baseline. The group in South Carolina reported smoking more grams-per-day of cannabis and more co-use of cigarettes. This differential use pattern may be more consistent with the use of high-potency cannabis in the California sample, which would paradoxically result in using fewer grams of cannabis (i.e., higher-potency cannabis would require a lower dose to get a similar or larger effect than low-potency cannabis). Indeed, such a use pattern has been previously described as a differentiator of cannabis use in states where marijuana is legal vs. illegal — cannabis users in 'legal' states are more likely to employ higher potency methods of cannabis use (dabs, vapes, etc.)<sup>72,73</sup> than in 'illegal' states. Higher potency cannabis and vape/dab use means are associated with more cannabis-related problems<sup>74-76</sup> and would be consistent with the higher average marijuana problem scale score and more DSM-5 CUD criteria met in the California sample. These site differences may account for the differential treatment effects as more impaired participants reporting more marijuana-related problems may have been more motivated to reduce the amount of cannabis they use. Non-specific site effects are also possible, though unlikely given that the study's principal investigator (GLS) was responsible for the conduct of the trial at both study sites. Time effects are also possible, especially since the COVID19 pandemic began just as the study transitioned from South Carolina to California (the sample that was recruited in California was enrolled after the onset of the pandemic, whereas the sample recruited in South Carolina was enrolled before the pandemic). Cannabis use increased broadly during the pandemic, and the isolation inherent in the pandemic potentially increased problematic cannabis use, making pandemic effects a possible contributor to the different populations<sup>77</sup>. Regardless of the site effects, there were suggestions of treatment efficacy at both sites, particularly in the important variable days-per-week of cannabis use. It is possible that the California participants with more severe CUD were motivated more for abstinence, and the South Carolina participants with less severe CUD were satisfied with reducing the number of days they used cannabis.

Several limitations of this study merit mentioning to add context to our findings. Methodologically, during data collection, we did not differentiate various means of cannabis use, and so in our data analysis, we were not able to differentiate participants with different methods of cannabis use. Given our initial concerns about retention rates<sup>39</sup>, we set the number of rTMS sessions (twenty total delivered over 10-visits), the density of visits (two-per-week), and inter-session interval (30-minutes), at the minimums we thought would have the potential to have an effect. We also used scalp-based targeting (Beam-F3) as opposed to more sophisticated targeting, such as MRI guided targeting, for feasibility and dissemination purposes. All of these compromises, though successful in terms of trial feasibility, may have resulted in a lower efficacy rate relative to a more optimized treatment paradigm including additional study-treatments<sup>78</sup>, an increased inter-session interval<sup>79</sup>, and a higher density of visits per week. Further, as this was a sequential rather than concurrent multi-site study, it is unclear if treatment by site interactions were a result of site differences or time differences. Finally, our analysis of days-per-week of cannabis use in the final two-weeks of follow-up was not pre-planned or corrected for multiple comparisons so we would categorize that finding as more hypothesis-generating for future work than hypothesis-proving.

## 5.0 Conclusions and Future Directions:

In summary, these preliminary findings suggest rTMS applied to the DLPFC holds promise in assisting participants with CUD to reduce their cannabis use, though further study with an optimized rTMS treatment paradigm and a longer follow-up period is needed to determine whether, in fact, such a treatment paradigm can develop into a standard of care intervention. Further study is warranted given the excellent safety profile found in this study, the high retention rate (demonstrating feasibility), and the promising clinical effect-sizes observed despite the relatively low dose of rTMS administered.

**Acknowledgments:** We would like to acknowledge the many contributors who made this study possible, including Amanda Wagner, Taylor Rodgers, Robert Malcolm, Lisa Nunn, Nick Bassano, and Alan Schatzberg.

## References:

1. Budney, A. J., Sofis, M. J. & Borodovsky, J. T. An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. *Eur Arch Psychiatry Clin Neurosci* **269**, 73–86 (2019).
2. Meier, M. H. Cannabis use and psychosocial functioning: evidence from prospective longitudinal studies. *Current Opinion in Psychology* **38**, 19–24 (2021).
3. Sahlem, G. L., Tomko, R. L., Sherman, B. J., Gray, K. M. & McRae-Clark, A. L. Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. *International Review of Psychiatry* **30**, 216–225 (2018).
4. Manthey, J., Freeman, T. P., Kilian, C., López-Pelayo, H. & Rehm, J. Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates. *The Lancet Regional Health - Europe* **10**, 100227 (2021).
5. Rhee, T. G. & Rosenheck, R. A. Admissions to substance use treatment facilities for cannabis use disorder, 2000–2017: Does legalization matter? *American J Addict* **31**, 423–432 (2022).
6. Hasin, D. S. *et al.* Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. *JAMA Psychiatry* **72**, 1235 (2015).
7. UNITED NATIONS OFFICE ON DRUGS AND LABOR. *WORLD DRUG REPORT 2020 (SET OF 6 BOOKLETS)*. (UNITED NATIONS, 2021).
8. Levy, N. S., Mauro, P. M., Mauro, C. M., Segura, L. E. & Martins, S. S. Joint perceptions of the risk and availability of Cannabis in the United States, 2002-2018. *Drug and Alcohol Dependence* **226**, 108873 (2021).
9. Patrick, M. *et al.* Monitoring the Future Panel Study annual report: National data on substance use among adults ages 19 to 60, 1976-2021. (2022).
10. Gray, K. M. *et al.* A Double-Blind Randomized Controlled Trial of *N*-Acetylcysteine in Cannabis-Dependent Adolescents. *AJP* **169**, 805–812 (2012).
11. Lintzeris, N. *et al.* Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial. *JAMA Intern Med* **179**, 1242 (2019).
12. Mariani, J. J. *et al.* Quetiapine treatment for cannabis use disorder. *Drug and Alcohol Dependence* **218**, 108366 (2021).
13. McRae-Clark, A. L. *et al.* Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. *Drug and Alcohol Dependence* **229**, 109111 (2021).
14. Davis, M. L. *et al.* Behavioral Therapies for Treatment-Seeking Cannabis Users: A Meta-Analysis of Randomized Controlled Trials. *Eval Health Prof* **38**, 94–114 (2015).
15. Brown, J. C. *et al.* NMDA-receptor agonist reveals LTP-like properties of 10-Hz rTMS in the human motor cortex. *Brain Stimulation* **14**, 619–621 (2021).
16. Deng, Z.-D., Lisanby, S. H. & Peterchev, A. V. Electric field depth–focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. *Brain Stimul* **6**, 1–13 (2013).
17. Huang, Y.-Z., Chen, R.-S., Rothwell, J. C. & Wen, H.-Y. The after-effect of human theta burst stimulation is NMDA receptor dependent. *Clinical Neurophysiology* **118**, 1028–1032 (2007).

18. Hanlon, C. A. *et al.* Probing the Frontostriatal Loops Involved in Executive and Limbic Processing via Interleaved TMS and Functional MRI at Two Prefrontal Locations: A Pilot Study. *PLoS One* **8**, (2013).
19. Hanlon, C. A., Dowdle, L. T., Moss, H., Canterberry, M. & George, M. S. Mobilization of Medial and Lateral Frontal-Striatal Circuits in Cocaine Users and Controls: An Interleaved TMS/BOLD Functional Connectivity Study. *Neuropsychopharmacol* **41**, 3032–3041 (2016).
20. Hanlon, C. A. *et al.* Left frontal pole theta burst stimulation decreases orbitofrontal and insula activity in cocaine users and alcohol users. *Drug and Alcohol Dependence* **178**, 310–317 (2017).
21. Blumberger, D. M. *et al.* Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. *The Lancet* **391**, 1683–1692 (2018).
22. Levkovitz, Y. *et al.* Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry* **14**, 64–73 (2015).
23. O'Reardon, J. P. *et al.* Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. *Biol Psychiatry* **62**, 1208–1216 (2007).
24. Carmi, L. *et al.* Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *AJP* **176**, 931–938 (2019).
25. Zangen, A. *et al.* Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. *World Psychiatry* **20**, 397–404 (2021).
26. Ekhtiari, H. *et al.* Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: A consensus paper on the present state of the science and the road ahead. *Neuroscience & Biobehavioral Reviews* **104**, 118–140 (2019).
27. McNeill, A. Continuous Theta Burst Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Impairs Inhibitory Control and Increases Alcohol Consumption. *Cogn Affect Behav Neurosci* **9** (2018).
28. Newman-Norlund, R. D., Gibson, M., McConnell, P. A. & Froeliger, B. Dissociable Effects of Theta-Burst Repeated Transcranial Magnetic Stimulation to the Inferior Frontal Gyrus on Inhibitory Control in Nicotine Addiction. *Front. Psychiatry* **11**, 260 (2020).
29. Rose, J. E. *et al.* Repetitive transcranial magnetic stimulation of the superior frontal gyrus modulates craving for cigarettes. *Biol Psychiatry* **70**, 794–799 (2011).
30. Sheffer, C. E. *et al.* Preventing relapse to smoking with transcranial magnetic stimulation: Feasibility and potential efficacy. *Drug Alcohol Depend* **182**, 8–18 (2018).
31. Kearney-Ramos, T. E. *et al.* Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* **3**, 599–609 (2018).
32. Li, X. *et al.* Transcranial magnetic stimulation of the dorsal lateral prefrontal cortex inhibits medial orbitofrontal activity in smokers: rTMS Effects on Brain Circuitry in Smokers. *Am J Addict* **26**, 788–794 (2017).
33. Li, X. *et al.* Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial. *Brain Stimulation* **13**, 1271–1279 (2020).

34. McCalley, D. M. *et al.* Medial Prefrontal Cortex Theta Burst Stimulation Improves Treatment Outcomes in Alcohol Use Disorder: A Double-Blind, Sham-Controlled Neuroimaging Study. *Biological Psychiatry Global Open Science* S2667174322000271 (2022) doi:10.1016/j.bpsgos.2022.03.002.
35. Harel, M. *et al.* Repetitive Transcranial Magnetic Stimulation in Alcohol Dependence: A Randomized, Double-Blind, Sham-Controlled Proof-of-Concept Trial Targeting the Medial Prefrontal and Anterior Cingulate Cortices. *Biological Psychiatry* **91**, 1061–1069 (2022).
36. Perini, I. *et al.* Repetitive transcranial magnetic stimulation targeting the insular cortex for reduction of heavy drinking in treatment-seeking alcohol-dependent subjects: a randomized controlled trial. *Neuropsychopharmacol.* **45**, 842–850 (2020).
37. Kearney-Ramos, T. & Haney, M. Repetitive transcranial magnetic stimulation as a potential treatment approach for cannabis use disorder. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **109**, 110290 (2021).
38. Sahlem, G. L., Baker, N. L., George, M. S., Malcolm, R. J. & McRae-Clark, A. L. Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users. *Am J Drug Alcohol Abuse* **44**, 47–55 (2018).
39. Sahlem, G. L. *et al.* A case series exploring the effect of twenty sessions of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and craving. *Brain Stimulation* **13**, 265–266 (2020).
40. Galletly, C., Gill, S., Clarke, P., Burton, C. & Fitzgerald, P. B. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? *Psychol. Med.* **42**, 981–988 (2012).
41. Harel, E. V. *et al.* H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study. *The World Journal of Biological Psychiatry* **15**, 298–306 (2014).
42. Kokdere, F. *et al.* Do deviations from the 5 sessions per week schedule impact outcomes of transcranial magnetic stimulation for major depressive disorder? *Brain Stimulation* **13**, 1491–1493 (2020).
43. Brief Counseling for Marijuana Dependence: A Manual for Treating Adults. 208.
44. Keel, J. C., Smith, M. J. & Wassermann, E. M. A safety screening questionnaire for transcranial magnetic stimulation. *Clinical Neurophysiology* **112**, 720 (2001).
45. Rossi, S. *et al.* Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. *Clinical Neurophysiology* **132**, 269–306 (2021).
46. Expert Panel on MR Safety: *et al.* ACR guidance document on MR safe practices: 2013. *J. Magn. Reson. Imaging* **37**, 501–530 (2013).
47. Sheehan, D. V. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10. *J Clin Psychiatry* **12**.
48. Hamilton, M. A rating scale for depression. *Journal of neurology, neurosurgery, and psychiatry* **23**, 56–62 (1960).



49. First, M. B., Williams, J. B. W., Karg, R. S. & Spitzer, R. L. Structured clinical interview for DSM-5—Research version (SCID-5 for DSM-5, research version; SCID-5-RV). *Arlington, VA: American Psychiatric Association* (2015).
50. Adamson, S. J. *et al.* An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R)☆. *Drug and Alcohol Dependence* **110**, 137–143 (2010).
51. Slavet, J. D. *et al.* The Marijuana Ladder: Measuring motivation to change marijuana use in incarcerated adolescents. *Drug and Alcohol Dependence* **83**, 42–48 (2006).
52. Allsop, D. J., Norberg, M. M., Copeland, J., Fu, S. & Budney, A. J. The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress. *Drug and Alcohol Dependence* **119**, 123–129 (2011).
53. Sobell, L. C. & Sobell, M. B. *Timeline Followback: A Technique for Assessing Self Reported Ethanol Consumption, Vol. 17.* (1992).
54. Karoly, H. C. *et al.* Investigating a novel fMRI cannabis cue reactivity task in youth. *Addict Behav* **89**, 20–28 (2019).
55. Heishman, S. J. *et al.* Reliability and Validity of a Short Form of the Marijuana Craving Questionnaire. *Drug Alcohol Depend* **102**, 35–40 (2009).
56. Baker, N. L. *et al.* Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. *Drug and Alcohol Dependence* **187**, 270–277 (2018).
57. McRae-Clark, A. L. *et al.* Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. *Psychopharmacology* **218**, 49–58 (2011).
58. Borckardt, J. J., Nahas, Z., Koola, J. & George, M. S. Estimating Resting Motor Thresholds in Transcranial Magnetic Stimulation Research and Practice: A computer Simulation Evaluation of Best Methods. *J ECT* **22**, 7 (2006).
59. Beam, W., Borckardt, J. J., Reeves, S. T. & George, M. S. An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. *Brain Stimulation* **2**, 50–54 (2009).
60. Brezing, C. A. *et al.* Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder: Quality of Life and Cannabis Treatment. *Am J Addict* **27**, 101–107 (2018).
61. Levin, F. R. *et al.* Non-abstinent treatment outcomes for cannabis use disorder. *Drug and Alcohol Dependence* **225**, 108765 (2021).
62. Sherman, B. J. *et al.* Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. *Psychology of Addictive Behaviors* **36**, 505–514 (2022).
63. Bonnet, U. & Preuss, U. W. The cannabis withdrawal syndrome: current insights. *Subst Abuse Rehabil* **8**, 9–37 (2017).
64. Carpenter, K. M., McDowell, D., Brooks, D. J., Cheng, W. Y. & Levin, F. R. A Preliminary Trial: Double-Blind Comparison of Nefazodone, Bupropion-SR, and Placebo in the Treatment of Cannabis Dependence. *Am J Addict* **18**, 53–64 (2009).
65. Levin, F. R. *et al.* Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. *Drug and Alcohol Dependence* **159**, 53–60 (2016).



66. Mason, B. J. *et al.* Gabapentin Treatment for Alcohol Dependence: A Randomized Controlled Trial. *JAMA Intern Med* **174**, 70–77 (2014).
67. McRae-Clark, A. L. *et al.* A Placebo-Controlled Trial of Atomoxetine in Marijuana-Dependent Individuals with Attention Deficit Hyperactivity Disorder: Atomoxetine in Marijuana-Dependent Individuals. *The American Journal on Addictions* **19**, 481–489 (2010).
68. McRae-Clark, A. L. *et al.* Bupirone treatment of cannabis dependence: A randomized, placebo-controlled trial. *Drug and Alcohol Dependence* **156**, 29–37 (2015).
69. McRae-Clark, A. L. *et al.* Vilazodone for cannabis dependence: A randomized, controlled pilot trial: Vilazodone for Cannabis Dependence. *Am J Addict* **25**, 69–75 (2016).
70. Weinstein, A. M. *et al.* Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. *The American Journal of Drug and Alcohol Abuse* **40**, 16–22 (2014).
71. Zhang, J. J. Q., Fong, K. N. K., Ouyang, R., Siu, A. M. H. & Kranz, G. S. Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. *Addiction* **114**, 2137–2149 (2019).
72. Borodovsky, J. T., Sofis, M. J., Sherman, B. J., Gray, K. M. & Budney, A. J. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints. *Psychology of Addictive Behaviors* **36**, 515–525 (2022).
73. Goodman, S., Wadsworth, E., Leos-Toro, C. & Hammond, D. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. *International Journal of Drug Policy* **76**, 102658 (2020).
74. Chadi, N., Minato, C. & Stanwick, R. Cannabis vaping: Understanding the health risks of a rapidly emerging trend. *Paediatrics & Child Health* **25**, S16–S20 (2020).
75. Freeman, T. P. *et al.* Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. *Addiction* **116**, 1000–1010 (2021).
76. Petrilli, K. *et al.* Association of cannabis potency with mental ill health and addiction: a systematic review. *The Lancet Psychiatry* **9**, 736–750 (2022).
77. Black, J. C., Amioka, E., Iwanicki, J. L., Dart, R. C. & Monte, A. A. Evaluation of Cannabis Use Among US Adults During the COVID-19 Pandemic Within Different Legal Frameworks. *JAMA Netw Open* **5**, e2240526 (2022).
78. Shevorykin, A. *et al.* Transcranial Magnetic Stimulation for Long-Term Smoking Cessation: Preliminary Examination of Delay Discounting as a Therapeutic Target and the Effects of Intensity and Duration. *Front. Hum. Neurosci.* **16**, 920383 (2022).
79. Williams, N. R. *et al.* High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. *Brain* **141**, e18–e18 (2018).


## Tables and Figures:

**Table-1:** Baseline and demographic characteristics of the Intent to Treat (ITT) sample. All values are reported  $\pm$  Standard Deviations. Cannabis use variables are reported for the 28-days prior to the screening and enrollment visit.

	Full Sample	Active	Sham
<b>Sample Demographics:</b>			
Age (Years)	30.2 $\pm$ 9.9	29.8 $\pm$ 9.9	30.7 $\pm$ 10.0
Sex	62.5% Male 37.5% Female	67.57% Male 32.43% Female	57.14% Male 42.86% Female
Ethnicity	81.7% non-Hispanic 15.5% Hispanic 2.8% Unknown	77.8% non-Hispanic 22.2% Hispanic 0% Unknown	85.7% non-Hispanic 8.6% Hispanic 5.7% Unknown
Race	45.8% Caucasian 25% Black / African American 15.3% Other 8.3% Asian 4.2% More than one 1.4% Native American	48.7% Caucasian 21.6% Black / African American 18.9% Other 8.1% Asian 2.7% More than one 0% Native American	42.9% Caucasian 28.6% Black / African American 11.4% Other 8.6% Asian 5.7% More than one 2.9% Native American
% $\geq$ 4-year college degree	33.3%	32.5%	34.3%
Marital Status (%married)	8.5%	5.6%	11.4%
Employment (%full time)	77.8%	81.1%	74.3%
% daily tobacco users	22.9%	25.7%	20%
HRSD <sub>24</sub> total score	3.6 $\pm$ 2.8	3.5 $\pm$ 2.9	3.8 $\pm$ 2.8
<b>Cannabis Use Disorder Characteristics:</b>			
Age of first cannabis use	15.6 $\pm$ 2.4	15.5 $\pm$ 2.0	15.7 $\pm$ 2.8
Age of onset of regular cannabis use	18.5 $\pm$ 4.5	18.9 $\pm$ 5.4	18.2 $\pm$ 3.5
% with prior quit attempts	90.3%	94.6%	85.7%
Longest period of abstinence (months)	5.0 $\pm$ 8.3	3.5 $\pm$ 5.9	6.6 $\pm$ 10.0
Number of DSM-5 CUD categories met	8.5 $\pm$ 1.5	8.5 $\pm$ 1.7	8.4 $\pm$ 1.3
CUDIT-R score	21.4 $\pm$ 5.1	21.3 $\pm$ 4.5	21.6 $\pm$ 5.7
Marijuana Problem Scale Score	9.9 $\pm$ 6.8	10.3 $\pm$ 6.8	9.4 $\pm$ 6.9
Mean Marijuana Contemplation Ladder score at baseline (1-10)	7.4 $\pm$ 1.0	7.5 $\pm$ 1.1	7.3 $\pm$ 0.9
Cannabis Withdrawal Scale symptom score with ad libitum use	39.9 $\pm$ 28.3	40.4 $\pm$ 29.4	39.3 $\pm$ 27.6
Cannabis Withdrawal Scale symptom score at 24-hours of abstinence	61.5 $\pm$ 39	65.4 $\pm$ 40.1	57.1 $\pm$ 38.1
<b>Baseline Cannabis Use Characteristics (Baseline 28-days):</b>			
Days of cannabis use	26.3 $\pm$ 3.9	26.2 $\pm$ 4.7	26.3 $\pm$ 2.9
Average number of cannabis use sessions per day	4.4 $\pm$ 3.3	4.2 $\pm$ 2.9	4.6 $\pm$ 3.7
Average grams of cannabis smoked per day	2.1 $\pm$ 2.8	1.6 $\pm$ 1.7	2.5 $\pm$ 3.6


CUDIT-R: Revised Cannabis Use Disorder Identification Test; HRSD<sub>24</sub>: 24-item Hamilton Rating Scale for Depression; DSM-5 CUD: Cannabis Use Disorder Criteria from the Diagnostic and Statistical Manual for Mental Disorders. There were no significant between group differences.

**Figure-1: Consort Flow Diagram of the overall sample.**  
**Enrollment (Total Sample—MUSC and Stanford)**




**Figure-2:** Craving as measured by the short form of the Marijuana Craving Questionnaire (MCQ-SF), before and after the delivery of the full course of rTMS. Mean MCQ-SF scores are reported with Standard Errors of the Means ( $\pm$ SEM).

**Figure 2: Change in Craving Pre- and Post- Treatment Course**



**Figure-3:** This figure depicts the number of self-reported weeks of abstinence. For this intent to treat sample missing data is imputed as non-abstinent. The 'total' percent weeks of abstinence is reported as the Relative Risk of having a week of abstinence in the follow-up period with the 95% confidence interval. Of note, when modeling between group differences in the four weeks of follow-up, and adjusting for site, the rate ratio of 1.66 does not meet statistical significance [95% CI: 0.84, 3.28];  $p=0.14$ .

**Figure 3: Weeks of Self-Reported Abstinence**



**Figure-4:** Days per week of cannabis use: This chart represents the number of days any cannabis was used in the preceding week. Scores are reported with Standard Errors of the Means ( $\pm$ SEM).

**Figure 4: Days-Per-Week of Cannabis Use**




Table 2: Adverse Events between groups.

	Total Sample, N, and (% of ITT sample—total / 72)	Active condition, N, and (% of ITT sample—total / 37)	Sham condition, N, and (% of ITT sample—total / 35)	Significance
# of participants with Any Adverse Events (%)	23 (31.9%)	16 (43.2%)	7 (20.0%)	$p=0.04$
Total number of Adverse events	30	19	11	$p=0.05$
Headache (%)	14 (19.4%)	10 (27.0%)	4 (11.4%)	<i>ns</i>
Fatigue (%)	9 (12.5%)	6 (16.2%)	3 (8.6%)	<i>ns</i>
Eye Twitch (%)	1 (1.4%)	1 (2.7%)	0 (0)	<i>ns</i>
Jaw Pain (%)	1 (1.4%)	1 (2.7%)	0 (0)	<i>ns</i>
Site discomfort (%)	1 (1.4%)	1 (2.7%)	0 (0)	<i>ns</i>
Insomnia (%)	1 (1.4%)	0 (0)	1 (2.9%)	<i>ns</i>
Irritability / mood swings (%)	1 (1.4%)	0 (0)	1 (2.9%)	<i>ns</i>
Hand numbness (%)	1 (1.4%)	0 (0)	1 (2.9%)	<i>ns</i>
Increased anxiety (%)	1 (1.4%)	0 (0)	1 (2.9%)	<i>ns</i>



## Supplemental Tables and Figures:

**Supplemental Figure-1: Experimental Timeline of Treatments and Assessments:**

	Immediate Pre-	Acute Treatment:	Immediate Post-	Follow Up Period			
	Prior to rTMS visit #1		Prior to rTMS visit #10	Week-1	Week-2	Week-3	Week-4
Aim-1: MCQ-SF	X	-Two rTMS-sessions per visit  -Two visits per week  -20-total sessions of active or sham rTMS delivered with cues  -Three-sessions of Motivational Enhancement Therapy	X				
Aim-2a: Weeks of Abstinence			X	X	X	X	
Aim-2a: Creatinine-Corrected Urine-Cannabinoids			X	X		X	
Aim-2b: Days-per-week of cannabis use	X		X	X	X	X	X

**Supplemental Table-1: Demographics comparison between Stanford and MUSC samples. Baseline and demographic characteristics in the Intent to Treat (ITT) sample between the MUSC and Stanford sites. All values are reported  $\pm$  Standard Deviations. Cannabis use variables are reported for the 28-days prior to the screening and enrollment visit.**

	Full Sample	MUSC	Stanford	Significance
<b>Sample Demographics:</b>				
Age (Years)	30.2 $\pm$ 9.93	31.4 $\pm$ 10.3	28.7 $\pm$ 9.4	ns
Sex	62.5% Male 37.5% Female	34.1% Female 65.9% Male	41.9% Female 58.1% Male	ns
Ethnicity	81.7% non-Hispanic 15.5% Hispanic 2.8% Unknown	92.5% non-Hispanic 2.5% Hispanic 5% Unknown	67.7% non-Hispanic 32.3% Hispanic 0% Unknown	$p=0.0008$
Race	45.8% Caucasian 25% Black / African American 15.3% Other 8.3% Asian 4.2% More than one 1.4% Native American	56.1% Caucasian 36.6% Black / African American 2.4% Other 0% Asian 2.4% More than one 2.4% Native American	33.3% Caucasian 9.7% Black / African American 32.3% Other 19.4% Asian 32.3% more than one 0% Native American	$p=0.0001$
% $\geq$ 4-year college degree	33.4%	31.7%	35.5%	ns
Marital Status (%married)	8.5%	7.5%	9.7%	ns
Employment (%full time)	77.8%	78.1%	77.4%	ns
% daily tobacco users	22.9%	35.9%	6.5%	$p=0.004$
<b>Cannabis Use Disorder Characteristics:</b>				
Age of first cannabis use	15.6 $\pm$ 2.4	15.3 $\pm$ 2.5	16.0 $\pm$ 2.3	ns
Age of onset of regular cannabis use	18.5 $\pm$ 4.5	19.0 $\pm$ 5.6	17.9 $\pm$ 2.5	ns
% with prior quit attempts	90.3%	92.7%	87.1%	ns
Longest period of abstinence (months)	5.0 $\pm$ 8.3	4.6 $\pm$ 9.1	5.6 $\pm$ 7.2	ns
Number of DSM-5 CUD categories met	8.5 $\pm$ 1.5	7.9 $\pm$ 1.5	9.2 $\pm$ 1.2	$p=0.001$
CUDIT-R score	21.4 $\pm$ 5.1	20.9 $\pm$ 4.8	22.2 $\pm$ 5.4	ns
Marijuana Problem Scale Score	9.9 $\pm$ 6.8	7.3 $\pm$ 5.6	13.2 $\pm$ 6.8	$p=0.0001$

Mean Marijuana Contemplation Ladder score at baseline (1-10)	7.4±1.0	7.5±1.1	7.3±1.0	ns
Cannabis Withdrawal Scale symptom score with ad libitum use	39.9±28.3	34.3±27.1	42.9±28.9	ns
Cannabis Withdrawal Scale symptom score at 24-hours of abstinence	61.5±39.0	56.2±41.3	64.6±37.9	ns
Baseline Cannabis Use Characteristics (Baseline 28-days):				
Days of cannabis use (last 28-days)	26.3±3.9	25.4±4.8	27.4±1.7	p=0.01
Average number of cannabis use sessions/day	4.4±3.3	3.8±3.2	5.2±3.4	ns
Average grams cannabis smoked/day	2.1±2.8	2.7±3.4	1.2±1.5	p=0.02

CUDIT-R: Revised Cannabis Use Disorder Identification Test; HRSD<sub>24</sub>: 24-item Hamilton Rating Scale for Depression; DSM-5 CUD: Cannabis Use Disorder Criteria from the Diagnostic and Statistical Manual for Mental Disorders

Supplemental Table-2: Integrity of the Blind

Group:	Guessed Active after first visit:	Confidence (0-Not confident at all, 4-Almost Certain)	Guessed Active after last visit:	Confidence: (0-Not confident at all, 4-Almost Certain)	Significance
Active Group	91.2%	1.3+1.2	61.5%	2.0+1.3	p=0.11 First p=0.96 Last
Sham Group	73.5%	1.6+1.1	60.9%	1.7+1.5	
Active MUSC	94.4%	1.3+1.2	45.5%	2.0+1.3	p=0.09 First p=0.67 Last
Sham MUSC	68.4%	1.6+1.1	60.0%	1.7+1.5	
Active Stanford	87.5%	1.3+1.0	73.3%	1.9+1.3	p=0.65 First p=0.69 Last
Sham Stanford	80.0%	1.5+1.2	61.5%	1.7+1.6	

Supplemental Table-3: Weeks of abstinence: Percent of participants in the intent to treat (ITT) sample who reported no cannabis use sessions over a week.

Full sample:	Self-Report abstinence (ITT)		Abstinence as verified by Urine Drug Testing (ITT)		Self-Report abstinence (Available Data)		Abstinence as verified by Urine Drug Testing (Available)	
	Active	Sham	Active	Sham	Active	Sham	Active	Sham
Total Tx9-4wk-FU:	14.9% (33/222)	9.0% (19/210)	10.8% (12/111)	5.7% (6/105)	20.4% (33/162)	13.9% (19/137)	14.8% (12/81)	8.8% (6/68)
Total F/U period only	15.5% (23/148)	9.3% (13/140)	10.8% (8/74)	4.3% (3/70)	21.3% (23/108)	14.4% (13/90)	14.8% (8/54)	6.8% (3/44)
Treatment visit 9	13.5% (5/37)	5.7% (2/35)			18.5% (5/27)	8.7% (2/23)		
Immediate post	13.5% (5/37)	11.4% (4/35)	10.8% (4/37)	8.6% (3/35)	18.5% (5/27)	16.7% (4/24)	14.8% (4/27)	12.5% (3/24)
1-week FU	16.2% (6/37)	22.9% (8/35)			22.2% (6/27)	34.8% (8/23)		
2-week FU	16.2% (6/37)	5.7% (2/35)	13.5% <sup>#</sup> (5/37)	2.9% <sup>#</sup> (1/35)	22.2% (6/27)	8.7% (2/23)	18.5% (5/27)	4.5% (1/22)
3-week FU	21.6% <sup>*</sup> (8/37)	2.9% <sup>*</sup> (1/35)			29.6% <sup>^</sup> (8/27)	4.6% <sup>^</sup> (1/22)		
4-week FU	8.1% (3/37)	5.7% (2/35)	8.1% (3/37)	5.7% (2/35)	11.1% (3/27)	9.1% (2/22)	11.1% (3/27)	9.1% (2/22)